Summary of Celldex Therapeutics FY Conference Call Company Overview - **Company**: Celldex Therapeutics (NasdaqCM:CLDX) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 04, 2026 Key Points Industry and Product Development - **Ongoing Studies**: Enrollment completion in the CSU and EMBARQ programs, and initiation of the phase 3 CIndU study [7][9] - **Excitement Around Drug**: Increased enthusiasm for the drug due to recent approvals of competitors like Remy and Dupixent [14][16] - **Study Powering**: Studies are 90% powered to detect a 10-point difference in Urticaria Activity Score 7 compared to placebo, applicable to both overall and refractory subsets [17][19] Clinical Data and Efficacy - **Phase 2 Study Results**: 76-week follow-up data showed a complete response rate of 41%, with 51% at 12 weeks and 71% at 52 weeks, indicating rapid and deepening responses [39] - **Omalizumab Refractory Population**: No approved treatments have shown statistically significant efficacy in this group, highlighting a market opportunity for Celldex [40] - **Comparison with Competitors**: Remy has not shown significant differences in the omalizumab-experienced population [42] Market Strategy and Positioning - **Market Entry Points**: Two potential entry points identified: frontline therapy for severe CSU and as a second-line option after existing therapies [89][91] - **Market Growth Potential**: Anticipation of significant market growth with the introduction of Repzido and Dupixent, which have historically been underdiagnosed [92] Pricing Strategy - **Pricing Considerations**: Currently evaluating pricing strategies, aiming for a premium compared to Dupixent, Olumiant, and Rinvoq [78] Future Studies and Trials - **Phase 2 Trials**: Completed enrollment for prurigo nodularis (PN) study with 140 patients, focusing on itch and skin clearance as primary endpoints [146][148] - **Atopic Dermatitis Study**: Similar design to PN study, with data expected later in the year [180][186] Regulatory and Safety Monitoring - **Adverse Event Monitoring**: Patients monitored monthly for neutropenia and other adverse events, with no significant association with infections noted [80] - **Sperm Study**: Ongoing study expected to read out in time for BLA filing, focusing on the impact of barzolvolimab on sperm count and hormone levels [82][84] Competitive Landscape - **Market Dynamics**: Increased competition expected to enhance diagnosis rates and treatment options in the CSU and CIndU markets [134][137] - **Differentiation Strategy**: Emphasis on rapid relief of itch and skin clearance as key differentiators in treatment efficacy [148] Conclusion - **Outlook**: An action-packed year ahead with multiple studies and potential market entries, positioning Celldex Therapeutics favorably in the competitive landscape of allergy and dermatology treatments [224][226]